 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, May 5, 2004, 24(18):4412-4420; doi:10.1523/JNEUROSCI.0477-04.2004
Previous Article | Next Article
Development/Plasticity/Repair
Glutamate Receptor-Mediated Oligodendrocyte Toxicity in Periventricular Leukomalacia: A Protective Role for Topiramate
Pamela L. Follett, Wenbin Deng, Weimin Dai, Delia M. Talos, Leon J. Massillon, Paul A. Rosenberg, Joseph J. Volpe, andFrances E. Jensen Department of Neurology and Program in Neuroscience, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Periventricular leukomalacia is a form of hypoxic–ischemic cerebral white matter injury seen most commonly in premature infants and is the major antecedent of cerebral palsy. Glutamate receptor-mediated excitotoxicity is a predominant mechanism of hypoxic–ischemic injury to developing cerebral white matter. We have demonstrated previously the protective effect of AMPA–kainate-type glutamate receptor blockade in a rodent model of periventricular leukomalacia. The present study explores the therapeutic potential of glutamate receptor blockade for hypoxic–ischemic white matter injury. We demonstrate that AMPA receptors are expressed on developing human oligodendrocytes that populate fetal white matter at 23–32 weeks gestation, the period of highest risk for periventricular leukomalacia. We show that the clinically available anticonvulsant topiramate, when administered post-insult in vivo, is protective against selective hypoxic–ischemic white matter injury and decreases the subsequent neuromotor deficits. We further demonstrate that topiramate attenuates AMPA–kainate receptor-mediated cell death and calcium influx, as well as kainate-evoked currents in developing oligodendrocytes, similar to the AMPA–kainate receptor antagonist 6-nitro-7-sulfamoylbenzo-(f)quinoxaline-2,3-dione (NBQX). Notably, protective doses of NBQX and topiramate do not affect normal maturation and proliferation of oligodendrocytes either in vivo or in vitro. Taken together, these results suggest that AMPA–kainate receptor blockade may have potential for translation as a therapeutic strategy for periventricular leukomalacia and that the mechanism of protective efficacy of topiramate is caused at least in part by attenuation of excitotoxic injury to premyelinating oligodendrocytes in developing white matter.
Key words: white matter; glutamate receptor; periventricular leukomalacia; topiramate; oligodendrocyte; excitotoxicity
Received Dec 23, 2003; revised March 25, 2004; accepted March 28, 2004.
This article has been cited by other articles:
D. J. Webber, M. van Blitterswijk, and S. Chandran
Neuroprotective Effect of Oligodendrocyte Precursor Cell Transplantation in a Long-Term Model of Periventricular Leukomalacia
Am. J. Pathol., December 1, 2009; 175(6): 2332 - 2342.
[Abstract] [Full Text] [PDF]
A. Desfeux, F. El Ghazi, S. Jegou, H. Legros, S. Marret, V. Laudenbach, and B. J. Gonzalez
Dual Effect of Glutamate on GABAergic Interneuron Survival during Cerebral Cortex Development in Mice Neonates
Cereb Cortex, September 16, 2009; (2009) bhp181v1.
[Abstract] [Full Text] [PDF]
W. Deng, J. Pleasure, and D. Pleasure
Progress in Periventricular Leukomalacia
Arch Neurol, October 1, 2008; 65(10): 1291 - 1295.
[Abstract] [Full Text] [PDF]
V. Gallo, J.-M. Mangin, M. Kukley, and D. Dietrich
Synapses on NG2-expressing progenitors in the brain: multiple functions?
J. Physiol., August 15, 2008; 586(16): 3767 - 3781.
[Abstract] [Full Text] [PDF]
S. M. Manning, D. M. Talos, C. Zhou, D. B. Selip, H.-K. Park, C.-J. Park, J. J. Volpe, and F. E. Jensen
NMDA Receptor Blockade with Memantine Attenuates White Matter Injury in a Rat Model of Periventricular Leukomalacia
J. Neurosci., June 25, 2008; 28(26): 6670 - 6678.
[Abstract] [Full Text] [PDF]
V. Degos, G. Loron, J. Mantz, and P. Gressens
Neuroprotective Strategies for the Neonatal Brain
Anesth. Analg., June 1, 2008; 106(6): 1670 - 1680.
[Abstract] [Full Text] [PDF]
O Khwaja and J J Volpe
Pathogenesis of cerebral white matter injury of prematurity
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2008; 93(2): F153 - F161.
[Abstract] [Full Text] [PDF]
B. Gerstner, T. M. DeSilva, K. Genz, A. Armstrong, F. Brehmer, R. L. Neve, U. Felderhoff-Mueser, J. J. Volpe, and P. A. Rosenberg
Hyperoxia Causes Maturation-Dependent Cell Death in the Developing White Matter
J. Neurosci., January 30, 2008; 28(5): 1236 - 1245.
[Abstract] [Full Text] [PDF]
M. Derrick, A. Drobyshevsky, X. Ji, and S. Tan
A Model of Cerebral Palsy From Fetal Hypoxia-Ischemia
Stroke, February 1, 2007; 38(2): 731 - 735.
[Abstract] [Full Text] [PDF]
T. Nakazawa, C. Nakazawa, A. Matsubara, K. Noda, T. Hisatomi, H. She, N. Michaud, A. Hafezi-Moghadam, J. W. Miller, and L. I. Benowitz
Tumor Necrosis Factor-{alpha} Mediates Oligodendrocyte Death and Delayed Retinal Ganglion Cell Loss in a Mouse Model of Glaucoma
J. Neurosci., December 6, 2006; 26(49): 12633 - 12641.
[Abstract] [Full Text] [PDF]
A. H. Hoon JR
Neuroimaging in Cerebral Palsy: Patterns of Brain Dysgenesis and Injury
J Child Neurol, December 1, 2005; 20(12): 936 - 939.
[Abstract] [PDF]
F. E. Jensen
Role of Glutamate Receptors in Periventricular Leukomalacia
J Child Neurol, December 1, 2005; 20(12): 950 - 959.
[Abstract] [PDF]
M. V. Johnston, D. M. Ferriero, S. J. Vannucci, and H. Hagberg
Models of Cerebral Palsy: Which Ones Are Best?
J Child Neurol, December 1, 2005; 20(12): 984 - 987.
[PDF]
N. G. Anderson, I. Laurent, N. Cook, L. Woodward, and T. E. Inder
Growth Rate of Corpus Callosum in Very Premature Infants
AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2685 - 2690.
[Abstract] [Full Text] [PDF]
R. Sankar and M. J. Painter
Neonatal seizures: After all these years we still love what doesn't work
Neurology, March 8, 2005; 64(5): 776 - 777.
[Full Text] [PDF]
|
|
|
|
 |
|